Clinical Trials Browser

INDUSTRY × Neoplasms × Classical hematology × Clear all

Embolism, Neoplasms, Venous Thromboembolism

NCT05635266 2024-05-07

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Classical hematologyGenitourinaryHead & NeckLymphoidOther hematologic neoplasmPlasma cell

red meat allergy, Alopecia Areata, Alzheimer Disease, Amyloidosis, Anemia, Sickle Cell, Arthritis, Asthma, Autistic Disorder, Behcet Syndrome, Celiac Disease, Colitis, Ulcerative, Crohn Disease, Cystic Fibrosis, Dermatitis, Atopic, Diabetes Mellitus, Epilepsies, Myoclonic, Fibrosis, Fibromyalgia, Graves Disease, Heart Diseases, Hepatitis, Hypersensitivity, Kidney Diseases, Leukemia, Lupus Erythematosus, Systemic, Lymphoma, Macular Degeneration, Multiple Sclerosis, Myasthenia Gravis, Neoplasms, Parkinson Disease, Pemphigus, Psoriasis, Schizophrenia, Spondylitis, Ankylosing, Thyroid Diseases, Vasculitis, Vitiligo, beta-Thalassemia, Hidradenitis Suppurativa, Hepatitis, Autoimmune, Stroke, Pulmonary Disease, Chronic Obstructive, Scleroderma, Diffuse

Clinical Trials

VICTORIE

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

MK-7962-012

Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens

H2H-OSCAR-US

PREDICARE

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Cancer Venous Thromboembolism (VTE)

FENSY

Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy

Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

TAR

Monitor-GCSF

An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

CARMEN

DOSE

Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

Thai Cancer Anemia Survey in Chulalongkorn Hospital

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

An Observational Study of Blood Management Techniques in Oncology Surgical Treatment

National Cancer Institute Thai Cancer Anemia Survey

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Darbepoetin Alfa and Anemia of Cancer

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

SAVE-ONCO

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

The Duration Study

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.